Exelixis | EXEL - Current Liabilities


Exelixis reported $405.64M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 277.11M 79.47M Dec/2025
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Akebia Therapeutics USD 162.94M 29.56M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
Bayer EUR 32.58B 3.63B Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Cytokinetics USD 202.45M 60.31M Dec/2025
Eisai JPY 387.67B 9.42B Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Esperion Therapeutics USD 300.81M 58.22M Dec/2025
Exelixis USD 405.64M 31.86M Dec/2025
Genmab DKK 1.43B 686M Dec/2025
Glaxosmithkline GBP 28.82B 144.79M Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
MacroGenics USD 43.11M 1.36M Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Moderna USD 1.99B 306M Dec/2025
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Novartis USD 27.28B 4.72B Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sanofi EUR 28.35B 9.32B Dec/2025
Takeda JPY 2.61T 470.53B Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Xencor USD 95.91M 9.42M Dec/2025